Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

Cryocrate presentation for zoom 3.26.19

58 vues

Publié le

Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.

Publié dans : Santé & Médecine
  • Soyez le premier à commenter

  • Soyez le premier à aimer ceci

Cryocrate presentation for zoom 3.26.19

  1. 1. Xu Han, Founder & CTO Tim Wheeler, CEO Life in Nano Ice Novel Cryopreservation Platform for Clinical and Research Applications
  2. 2. About CryoCrate Platform Technology Across Multiple Markets  Vision: Worldwide leader in cryopreservation technology  Long-term cell and tissue preservation Current Products: • Liquid media – Commercial, now selling through Fisher Scientific • Tissues for research– Cornea feasibility complete, ready to sell • Tissues for transplantation – Need 510(k) clearance for cornea device Products under development • Ultrafast freezing technology – R&D phase nearly complete • Organs – R&D phase, focusing on hearts
  3. 3. Market Pain Points  Technology Challenges • Some cells cannot be stored  Liquid Nitrogen Storage • Safety & cost  Use of Animal Sera • Rising costs • Lot-to-lot validation required  Tissue Processing Costs • 24/7/365 operational cycle  Tissue Viability • 7-10 days typical, 14-day max • Missed revenue opportunities  Tissue Availability • Global demand >>> supply 30:1 • 97% of patients globally will NOT get cornea transplants NEEDS Better formulae Serum-free -80o C storage NEEDS Cost reductions Longer-term tissue life More tissue availability CELL PRESERVATION CORNEA MANAGEMENT
  4. 4. Addressing Market Needs C80EZ® & IcyEYE™  -80o C storage  $30M to $60M savings/year  Extend tissue life >6 months  More cornea transplants  Better-quality tissues for research and training  PCT filing pending IcyEYE™ CORNEA MANAGEMENTCELL PRESERVATION C80EZ®  -80 o C storage  Serum not required  Enabling for many 1o cells  Full viability post-thaw  Time & material savings  IP: Nationalized PCT “Having the ability to preserve corneas beyond the current two-week shelf life would revolutionize the global cornea transplant market.” --Ophthalmologist
  5. 5. Novel Platform Technology and Product Line “Nano Ice” in C80EZ® media  Creates unique cubic ice  Reduces ice crystal size  Minimizes cell damage  Enables long-term storage in -80o C freezers Current C80EZ® Cell Applications  Cardiovascular  Cancer  Kidney  Insect New Products  IcyEYETM cornea kit (media + device)  C80EZ® Neuron for primary neurons
  6. 6. Competitive Overview and Positioning  IcyEYE™ is the only technology that can enable long-term cornea storage  Ideal Customer Profile • Cornea researcher • Eye Bank processing tissue for transplantation • Eye Bank exporting surplus tissues  Highly Competitive  Many suppliers + homebrew  Distribution channels are key  Ideal Customer Profile: • Using primary cells • Prefer -80o C vs liquid nitrogen • Moving away from animal serum “The ability to freeze corneas shortly after collection would greatly improve the quality of corneas that we export as well as increase the number of corneas available for export.” - Eye Bank CEO C80EZ® IcyEYE™ CELL PRESERVATION CORNEA MANAGEMENT
  7. 7. Go-To Market Highlights $200K$55K $17M$3M $9M Exit •$1M Funding • Sales Team • Production Staff • Consultants • IcyEYE™ PCT •Icy EYE™ FDA Clearance •Personnel $26M • GMP Manufacturing • FDA Meeting • Beta Eye Banks • IcyEYE™ Nationalization Sales Revenues 2019 2020 2021 20232022 2024 Scale Production Potential Acquirers  >$600M global market, 10-20% CAGR  Distribution sales thru Fisher Scientific  Thousands of researchers  Expand sales team (2019)  GMP production (2020)  $2M sales in 2024  >$60M global market, 5-10% CAGR  Direct sales  70+ eye banks in the US  Media for research cornea (2019)  FDA clearance early 2021  $24M sales in 2024 CELL PRESERVATION CORNEA MANAGEMENT
  8. 8. Management Team Business and R&D  Tim Wheeler, M.S., D.B.A. (CEO) • 30+ years, business executive, marketing, sales, ecommerce • Worked for GE, Fisher Scientific, Millipore Sigma, BioMerieux  Xu Han, Ph.D. (President & CTO) • Founded CryoCrate in 2012 • NIH and NIFA SBIRs, Coulter Awardee, • MU Faculty Innovation Award and MU IP Fast-track Awards • >$2M funding – Grants & 2017 seed investment Advisory Board  P. Koulen, Ph.D. (Director, Vision Research Center)  F. Fraunfelder, M.D., M.B.A. (Chair, MU Ophthalmology)  R. Roberts, Ph.D. (Member, National Academy of Sciences)  H. White, Ph.D. & D. Keller (Centennial Investors Angel Network)  B. Turpin & Q. Messbarger (Directors, Missouri Innovation Center, Inc.)
  9. 9. Near-Term Recruitment and Collaboration Chief Operating Officer: • Regulatory professionals (FDA medical device) • cGMP manufacturing and production • Business operation and acquisition Sales • Experience in cell culture or tissue engineering • Working with Fisher representatives in mid USA Partners: • GMP production of chemically defined media • GMP production of devices (injection molding)
  10. 10. CryoCrate Projections 2019 to 2024 Distribution Sales • Liquid media only • $200/bottle • Distribution – Fisher Scientific • Academia & biopharma IcyEYE™ Sales • $200/cornea: Device + media • Direct channel • US eye banks main target • China, India, & EU secondary targets Cornea Research •Liquid media only •$75/cornea •Direct channel •Eye banks & academia -$5,000,000 $0 $5,000,000 $10,000,000 $15,000,000 $20,000,000 $25,000,000 $30,000,000 2019 2020 2021 2022 2023 2024 IcyEye™ C80EZ® Cornea C80EZ® Cell Media EBITDA
  11. 11. Xu Han, Founder & CTO | xu.han@cryocrate.com | 573-268-9501 Tim Wheeler, CEO | timothy.wheeler@cryocrate.com | 636-875-8297 Thank You!

×